Risk Stratification in Patients With Preserved Ejection Fraction
PRESERVE-EF
Post Myocardial Infarction Risk Stratification for Sudden Cardiac Death in Patients With Preserved Ejection Fraction: PRESERVE-EF
1 other identifier
observational
575
1 country
1
Brief Summary
The purpose of the study is to assess the prevalence and the prognostic value of non-invasive indexes and programmed ventricular stimulation for sudden cardiac death in post-myocardial infarction (MI) patients with left ventricular ejection fraction (LVEF)\>40%.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 24, 2014
CompletedFirst Posted
Study publicly available on registry
April 28, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2018
CompletedResults Posted
Study results publicly available
August 26, 2019
CompletedSeptember 4, 2019
August 1, 2019
4.3 years
April 24, 2014
April 16, 2019
August 23, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or Implantable Cardioverter - Defibrillator (ICD) Activation
The number of patients from each risk level group meeting the primary endpoint will be used to assess diagnostic accuracy (positive/negative predictive value, sensitivity and specificity) of the proposed two-stage, PVS-inclusive, risk stratification approach for the allocation of an ICD
From stratification completion (i.e. allocation to one of three risk level groups) until either occurrence of primary endpoint or study completion (mean 32months) - study stopped early due to emergence of clearly defined high risk subgroup
Secondary Outcomes (1)
Total Mortality
From completion of risk stratification to study completion or outcome occurrence (mean 32 months)
Study Arms (1)
Post-MI patients
Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation (PVS) will be performed in high-risk patients based on non-invasive evaluation. ICD implantation will be performed in patients with induced ventricular tachycardia (VT) upon PVS
Interventions
Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
ICD implantation in patients with induced VT in programmed ventricular stimulation
Eligibility Criteria
1000 asymptomatic post-MI patients\>40%, at least 40 days post-MI, revascularized or without needing further revascularization (in any case without any evidence of ischemia) The patients will be divided into two categories: 1. Asymptomatic patients with revascularized STEMI (remaining stenoses in non culprit vessels \<70%) at 40 days post-MI (when LVEF\>40% will be re-assessed) 2. Asymptomatic patients late after MI (initially STEMI-NSTEMI at discharge Q-non Q) with LVEF\>40% right after a negative stress test or right after a negative for stenoses control coronary catheterization
You may qualify if:
- Asymptomatic patients with revascularized STEMI (remaining stenoses in non culprit vessels \<70%) at 40 days post-MI (when LVEF\>40% will be re-assessed)
- Asymptomatic patients late after MI (initially STEMI-NSTEMI at discharge Q-non Q) with LVEF\>40% right after a negative stress test or right after a negative for stenoses control coronary catheterization
You may not qualify if:
- Episodes of sustained VT or aborted sudden cardiac death (SCD) 48 hours after the acute MI phase.
- Episodes of syncope within the last 6 months
- Cancer, liver failure (cirrhosis), end-stage renal disease
- Use of anti-arrhythmic drugs other than b-blockers
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Athenslead
- Medtroniccollaborator
- General Electriccollaborator
Study Sites (1)
First Cardiology Clinic, Hippokration Hospital
Athens, 11527, Greece
Related Publications (1)
Gatzoulis KA, Tsiachris D, Arsenos P, Antoniou CK, Dilaveris P, Sideris S, Kanoupakis E, Simantirakis E, Korantzopoulos P, Goudevenos I, Flevari P, Iliodromitis E, Sideris A, Vassilikos V, Fragakis N, Trachanas K, Vernardos M, Konstantinou I, Tsimos K, Xenogiannis I, Vlachos K, Saplaouras A, Triantafyllou K, Kallikazaros I, Tousoulis D. Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study. Eur Heart J. 2019 Sep 14;40(35):2940-2949. doi: 10.1093/eurheartj/ehz260.
PMID: 31049557DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
Study was not a randomized clinical trial since almost all patients with a per protocol indication received a device, without the presence of a high-risk control group, thus potentially overestimating true arrhythmic risk.
Results Point of Contact
- Title
- Professor Konstantinos A. Gatzoulis
- Organization
- First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens
Study Officials
- PRINCIPAL INVESTIGATOR
Konstantinos Gatzoulis, MD, PhD
University of Athens, Hippokration Hospital
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assoc. Professor of Cardiology
Study Record Dates
First Submitted
April 24, 2014
First Posted
April 28, 2014
Study Start
April 1, 2014
Primary Completion
July 31, 2018
Study Completion
July 31, 2018
Last Updated
September 4, 2019
Results First Posted
August 26, 2019
Record last verified: 2019-08